Duke Licenses NPM1 from Trovagene for AML Research, Testing
December 27, 2012
Duke Licenses NPM1 from Trovagene for AML Research, Testing
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Genoptix Joins Growing List of Companies Licensing TrovaGene's NPM1 for AML Testing
January 2, 2013 / Pharmacogenomics Reporter - Skyline Licenses TrovaGene Biomarker for AML
June 21, 2010 / GenomeWeb Daily News - In Gene Patent Ruling, SCOTUS Draws Line Between Product of Nature and Invention
June 19, 2013 / Pharmacogenomics Reporter - Innovation Boom or Bust? Industry Gauges Impact of SCOTUS Ruling on Gene Patents
June 19, 2013 / Pharmacogenomics Reporter - Trovagene's Q1 Revenues Rise
May 15, 2013 / GenomeWeb Daily News